Search research articles
Contact Us
Filters
Showing results (31-40 of 43) with videos related to
Page
of 5
Sort By:
Experimental Hematology
|
September 23, 2022
Transcriptomic Signatures of Hypomethylating Agent Failure in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
Faezeh Darbaniyan, Hong Zheng, Rashmi Kanagal-Shamanna, et al.
Leukemia Research
|
January 31, 2021
Type I interferon upregulation and deregulation of genes involved in monopoiesis in chronic myelomonocytic leukemia
Guillermo Montalban-Bravo, Faezeh Darbaniyan, Rashmi Kanagal-Shamanna, et al.
American Journal of Hematology
|
September 4, 2020
Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3)
Koji Sasaki, Guillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
September 10, 2023
Geographic Disparity of Outcome in Patients With Cancer Over Decades: The Surveillance, Epidemiology, and End Results
Koji Sasaki, Kiyomi Morita, Hagop Kantarjian, et al.
Cancer
|
June 23, 2021
Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes
Rashmi Kanagal-Shamanna, Guillermo Montalban-Bravo, Koji Sasaki, et al.
Cancer
|
March 13, 2019
Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome
Kiran Naqvi, Koji Sasaki, Guillermo Montalban-Bravo, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 22, 2024
Artificial Intelligence Assessment of Chest Radiographs for COVID-19
Koji Sasaki, Guillermo Garcia-Manero, Masayuki Nigo, et al.
American Journal of Hematology
|
November 12, 2020
The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes
Koji Sasaki, Elias J Jabbour, Farhad Ravandi, et al.
Blood Advances
|
February 7, 2020
Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes
Guillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Christopher B Benton, et al.
British Journal of Haematology
|
August 2, 2021
Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome
Kelly S Chien, Kunhwa Kim, Graciela M Nogueras-Gonzalez, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 43) with videos related to
Sort By:
Page
of 5
Experimental Hematology
|
September 23, 2022
Transcriptomic Signatures of Hypomethylating Agent Failure in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
Faezeh Darbaniyan, Hong Zheng, Rashmi Kanagal-Shamanna, et al.
Leukemia Research
|
January 31, 2021
Type I interferon upregulation and deregulation of genes involved in monopoiesis in chronic myelomonocytic leukemia
Guillermo Montalban-Bravo, Faezeh Darbaniyan, Rashmi Kanagal-Shamanna, et al.
American Journal of Hematology
|
September 4, 2020
Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3)
Koji Sasaki, Guillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
September 10, 2023
Geographic Disparity of Outcome in Patients With Cancer Over Decades: The Surveillance, Epidemiology, and End Results
Koji Sasaki, Kiyomi Morita, Hagop Kantarjian, et al.
Cancer
|
June 23, 2021
Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes
Rashmi Kanagal-Shamanna, Guillermo Montalban-Bravo, Koji Sasaki, et al.
Cancer
|
March 13, 2019
Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome
Kiran Naqvi, Koji Sasaki, Guillermo Montalban-Bravo, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 22, 2024
Artificial Intelligence Assessment of Chest Radiographs for COVID-19
Koji Sasaki, Guillermo Garcia-Manero, Masayuki Nigo, et al.
American Journal of Hematology
|
November 12, 2020
The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes
Koji Sasaki, Elias J Jabbour, Farhad Ravandi, et al.
Blood Advances
|
February 7, 2020
Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes
Guillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Christopher B Benton, et al.
British Journal of Haematology
|
August 2, 2021
Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome
Kelly S Chien, Kunhwa Kim, Graciela M Nogueras-Gonzalez, et al.
Page
of 5